基于核酸适配体的甲胎蛋白生物传感器研究进展

甲胎蛋白（AFP）与肝癌及多种肿瘤的发生发展密切相关,临床上已作为原发性肝癌的血清标志物,用于原发性肝癌的诊断及疗效检测。近年来,随着分子生物技术的进步,基于AFP核酸适配体的生物传感器不断涌现,取得了一些检测方法的新突破。本文综述了基于核酸适配体的AFP生物传感器分析方法的开发与应用情况,为开发新的高灵敏度、高选择性和高特异性AFP分析方法提供参考。     

细菌的核酸适配体筛选的研究进展

核酸适配体(aptamer)是通过指数富集配体系统进化技术(SELEX)筛选的能够以高亲和力和高特异性识别靶标分子或细胞的核糖核酸(RNA)和单链脱氧核糖核酸(ssDNA)。作为化学抗体,核酸适配体的制备和合成比抗体的成本更低。核酸适配体的靶标范围极其广泛,包括小分子、生物大分子、细菌和细胞等。针对细菌靶标筛选的适配体,目前主要应用于食品、医药和环境中的细菌检测。细菌的核酸适配体筛选可以通过离心法将菌体-适配体复合物与游离的适配体分离,并通过荧光成像、荧光光谱分析、流式细胞仪分选、DNA捕获元件、酶联适配体分析等方法表征适配体与靶标的相互作用。筛选出的适配体可结合生物、化学检测方法用于细菌检测。本文介绍了细菌适配体的筛选和表征方法以及基于适配体的检测方法的最新进展,分析了不同检测方法的利弊,并列出了2011~2015年筛选的细菌的核酸适配体。     

光学适配体传感器检测赭曲霉毒素A的研究进展

赭曲霉毒素A(Ochratoxin A,OTA)是真菌产生的次级代谢产物,性质稳定,不易去除,人体摄入后将产生严重的健康危害。数十年来,核酸适配体不断发展,成为生物传感器的重要识别元件之一,适体传感器被广泛用于生物、医药、疾病等分析检测。本文总结了用于检测OTA的经典方法和基于核酸适配体的生物传感器方法,并主要从光学适配体传感器方面阐述了近年用于检测赭曲霉毒素A的适配体传感器,并对其进行了总结和展望。     

核酸适配体在微流控芯片中筛选及病毒性疾病中应用

核酸适配体是短的、单链DNA或RNA序列。相较于抗体成本高、不稳定、免疫原性、难修饰的问题,核酸适配体作为新一代亲和试剂,有着免疫原性低、易修饰、靶标范围广等优势。通过指数富集配体系统进化技术(Systematic Evolution of Ligands by Exponential Enrichment,SELEX)可获得与靶标分子特异性结合的核酸适配体,而如何提高核酸适配体筛选效率是核酸适配体广泛应用的一个瓶颈问题。目前,提高核酸适配体筛选效率的方法种类较多,而微流控SELEX的发展,加速了核酸适配体的发现。核酸适配体作为各种靶标的识别分子,具有诊断和治疗特定疾病的潜力。鉴于此,本文重点介绍核酸适配体在微流控芯片领域进行筛选的研究进展,以及阐述其在病毒性疾病中的应用以及展望。     

全细胞的核酸适配体筛选的研究进展

核酸适配体(aptamer)是从人工合成的随机单链DNA(ssDNA)或RNA文库中筛选得到的,能够高亲和力、高特异性地与靶标结合的ssDNA或RNA。核酸适配体的靶标范围广,可包括小分子、蛋白质、细胞、微生物等多种靶标。其中以细胞为靶标的适配体在生物感应、分子成像、医学诊断、药物传输和疾病治疗等领域有很大的应用潜能。但全细胞的核酸适配体筛选过程复杂,筛选难度大,筛选的适配体性能不佳是导致目前可用的适配体非常有限的主要原因。由于细胞表面蛋白质在提取纯化过程中分子结构和形态会发生改变,故以膜表面蛋白质为靶标筛选的适配体很难应用于识别整体细胞。以全细胞为靶标的核酸适配体筛选则不需要准确了解细胞表面的分子结构,筛选过程中可保持细胞的天然状态,以全细胞为靶标筛选出的核酸适配体有望直接用于全细胞识别。本文总结了2008~2015年全细胞的核酸适配体筛选的研究进展,介绍了靶细胞的分类、核酸库的设计、筛选条件和方法以及核酸适配体的亲和力表征方法等。并列出全细胞靶标的核酸适配体序列。     

基于核酸适配体的比色生物传感器研究进展

核酸适配体因能与目标物特异性结合而被用作生物识别元件,广泛用于生物传感器的研究。基于适配体的比色生物传感器,因简便、经济且直观可视等特点,在环境保护、医疗诊断和食品安全等领域备受青睐。随着生物技术和纳米技术的迅速发展,结合不同显色途径和信号放大方法,已建立了多种操作简便、特异性强、灵敏度高的基于适配体的比色传感方法,为现场快速检测技术的发展提供了新思路和新选择。识别元件、信号探针及信号放大策略都是影响比色生物传感器准确性和灵敏度的重要因素,纳米材料和放大策略的选择及设计非常重要。本文主要基于酶催化和等离子体共振比色原理,介绍了近年来比色适配体传感器的研究进展,为高灵敏比色生物传感器的研究和应用提供参考。     

基于核酸适配体和纳米粒子的光学探针

核酸适配体(aptamer)是一类通过指数富集的配体系统进化技术(SELEX)经体外筛选得到的单链DNA或RNA。核酸适配体借自身形成的空间结构与靶标分子特异性结合,具有靶分子广、亲和力高、特异性强、易改造修饰等特点,因而在生命科学、临床诊断、药物发现和环境科学等方面得以广泛应用。近年来,核酸适配体与纳米技术结合,并利用纳米材料在光学、磁学、电学、化学及生物学方面表现出的特殊性质,实现了对靶标分子高灵敏度、高选择性、简便快速的识别与检测。本文评述了基于核酸适配体-纳米粒子特性的光学探针在生物大分子、金属离子和有机小分子检测等领域的应用现状与发展趋势,主要包括比色法、荧光光谱法、表面增强拉曼光谱法等。     

核酸适配体传感器在黄曲霉毒素B1检测中应用研究进展北大核心CSCD

核酸适配体作为一种新型识别分子,具有亲和力高、稳定性强、制备成本低、特异性强等优点,但其自身不具有信号转换功能,它与靶标分子特异性结合过程,不可产生被检测的物理化学信号。因此,需将核酸适配体与靶标分子特异性识别结合过程转为易于被检测的物理化学信号变化的过程。根据信号转换方式的不同,可将适配体生物传感器分为荧光适配体传感器、比色适配体传感器、电化学适配体传感器和表面拉曼散射适配体传感器。本文对基于以上4种检测信号的核酸适配体生物传感器在黄曲霉毒素(AFB1)检测方面的应用进行综述,并概述该类传感器应用前景和当前面临的挑战。     

胃腺癌核酸适配体的筛选与特异性研究

核酸适配体可作为分子探针应用于胃腺癌的早期诊断和治疗,具有广泛应用前景。本实验利用Serum-SELEX（Ser-SELEX）技术筛选胃腺癌核酸适配体。通过对候选适配体二级结构分析,其二级结构多为茎环结构。圆二色谱分析显示,7条候选核酸适配体呈右手螺旋特征。通过荧光定量核酸扩增检测系统（q-PCR）检测了候选核酸适配体对胃腺癌靶标的亲和力,表明候选核酸适配体浓度梯度与Ct值均呈正相关,亲和力常数为纳摩尔级别。利用q-PCR法、量子点法验证了候选核酸适配体识别靶标的特异性,结果均显示Apt-101对靶标亲和力更高,特异性更强,Apt-101的平衡解离常数（K_d值）为6.444±1.128nmol/L,特异性检测阳性率大于70%。     

核酸适配体功能化的稀土上转换纳米材料在生物检测中的应用

稀土上转换纳米材料可以吸收近红外光并发射出可见光或紫外光,在生物传感领域得到了广泛研究。核酸适配体能高特异性和高亲和性地与靶标物结合,被广泛应用于生物传感、疾病诊断等领域。将稀土上转换纳米材料与核酸适配体结合构建的检测体系,可实现对目标物灵敏、高选择性的检测。本文介绍了近几年核酸适配体功能化的稀土上转换纳米材料在生物小分子、蛋白质、核酸、病原微生物、细胞等方面的应用,并展望了其在分析检测领域的发展前景。     

Serum Proteomics in Biomedical Research: A Systematic Review

Proteins that are important indicators of physiological or pathological states may contribute to the early diagnosis of disease, which may provide a basis for identifying the underlying mechanism of disease development. Serum, contains an abundance of proteins, offers an easy and inexpensive approach for disease detection and possesses a high potential to revolutionize the diagnostics. These differentially expressed proteins in serum have become an important role to monitoring the state for disease. Availability of emerging proteomic techniques gives optimism that serum can eventually be placed as a biomedium for clinical diagnostics. Advancements have benefited biomarker research to the point where serum is now recognized as an excellent diagnostic medium for the detection of disease. Comprehensive proteome of human serum fluid with high accuracy and availability has the potential to open new doors for disease biomarker discovery and for disease diagnostics, providing insights useful for future study. Thus, this review presents an overview of the value of serum as a credible diagnostic tool, and we aim to summarize the proteomic technologies currently used for global analysis of serum proteins and to elaborate on the application of serum proteomics to the discovery of disease biomarkers, and discuss some of the critical challenges and perspectives for this emerging field.     

High-sensitivity nanosensors for biomarker detection

High sensitivity nanosensors utilize optical, mechanical, electrical, and magnetic relaxation properties to push detection limits of biomarkers below previously possible concentrations. The unique properties of nanomaterials and nanotechnology are exploited to design biomarker diagnostics. High-sensitivity recognition is achieved by signal and target amplification along with thorough pre-processing of samples. In this tutorial review, we introduce the type of detection signals read by nanosensors to detect extremely small concentrations of biomarkers and provide distinctive examples of high-sensitivity sensors. The use of such high-sensitivity nanosensors can offer earlier detection of disease than currently available to patients and create significant improvements in clinical outcomes.     

A Renal-Clearable Macromolecular Reporter for Near-Infrared Fluorescence Imaging of Bladder Cancer

Bladder cancer (BC) is a prevalent disease with high morbidity and mortality; however, in vivo optical imaging of BC remains challenging because of the lack of cancer-specific optical agents with high renal clearance. Herein, a macromolecular reporter (CyP1) was synthesized for real-time near-infrared fluorescence (NIRF) imaging and urinalysis of BC in living mice. Because of the high renal clearance (ca. 94 % of the injection dosage at 24 h post-injection) and its cancer biomarker (APN=aminopeptidase N) specificity, CyP1 can be efficiently transported to the bladder and specially turn on its NIRF signal to report the detection of BC in living mice. Moreover, CyP1 can be used for optical urinalysis, permitting the ex vivo tracking of tumor progression for therapeutic evaluation and easy translation of CyP2 as an in vitro diagnostic assay. This study not only provides new opportunities for non-invasive diagnosis of BC, but also reveals useful guidelines for the development of molecular reporters for the detection of bladder diseases.     

A Renal‐Clearable Macromolecular Reporter for Near‐Infrared Fluorescence Imaging of Bladder Cancer

Bladder cancer (BC) is a prevalent disease with high morbidity and mortality; however, in vivo optical imaging of BC remains challenging because of the lack of cancer‐specific optical agents with high renal clearance. Herein, a macromolecular reporter (CyP1) was synthesized for real‐time near‐infrared fluorescence (NIRF) imaging and urinalysis of BC in living mice. Because of the high renal clearance (ca. 94 % of the injection dosage at 24 h post‐injection) and its cancer biomarker (APN=aminopeptidase N) specificity, CyP1 can be efficiently transported to the bladder and specially turn on its NIRF signal to report the detection of BC in living mice. Moreover, CyP1 can be used for optical urinalysis, permitting the ex vivo tracking of tumor progression for therapeutic evaluation and easy translation of CyP2 as an in vitro diagnostic assay. This study not only provides new opportunities for non‐invasive diagnosis of BC, but also reveals useful guidelines for the development of molecular reporters for the detection of bladder diseases.     

Microfluidic systems for the analysis of blood-derived molecular biomarkers

Biomarkers are relevant indicators of the physiological state of an individual. Although biomarkers can be found in diseased tissue and different biofluids, sampling from blood plasma is relatively easy and less invasive. Among the molecular biomarkers that can be found circulating in plasma are proteins, metabolites, nucleic acids, and exosomes. Some of these plasma-circulating biomarkers are now employed for patient stratification in a broad range of diseases with high sensitivity and specificity and are useful in early diagnosis, initial risk assessment, and therapy selection. However, there is a pressing need to develop novel approaches for biomarker analysis that can be translated into clinical or other settings without complex methodologies or instrumentation. Microfluidics has been touted as a promising technology to carry out this task because it offers high-throughput, automation, multiplexed detection, and portability, possibly overcoming the bottleneck that prevent the translation of novel biomarkers to the point-of-care (POC). Here, we provide a review of the microfluidic systems that have been engineered to detect circulating molecular biomarkers in blood plasma. We also review the different microfluidic approaches for plasma enrichment, which are now being integrated with microfluidic-based biomarker analyzers. Such integration should lead to cost-effective solutions in in vitro diagnostics, with special relevance to POC platforms.     

Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer

Ovarian cancer is the most lethal gynecologic malignancy among women. Approximately 70–80% of patients with advanced ovarian cancer experience relapse within five years and develop platinum-resistance. The short life expectancy of patients with platinum-resistant or platinum-refractory disease underscores the need to develop new and more effective treatment strategies. Early detection is a critical step in mitigating the risk of disease progression from early to an advanced stage disease, and protein biomarkers have an integral role in this process. The best biological diagnostic tool for ovarian cancer will likely be a combination of biomarkers. Targeted proteomics methods, including mass spectrometry-based approaches, have emerged as robust methods that can address the chasm between initial biomarker discovery and the successful verification and validation of these biomarkers enabling their clinical translation due to the robust sensitivity, specificity, and reproducibility of these versatile methods. In this review, we provide background information on the fundamental principles of biomarkers and the need for improved treatment strategies in ovarian cancer. We also provide insight into the ways in which mass spectrometry-based targeted proteomics approaches can provide greatly needed solutions to many of the challenges related to ovarian cancer biomarker development.     

Rapid Detection of Serum Procalcitonin by Immunochromatograghy Technology Based on Freeze‐dried Up‐conversion Nanoparticles/Antibody Conjugates

Procalcitonin (PCT) is a sensitive and specific biomarker for sepsis diagnosis and widely used as a biomarker to improve the diagnosis of bacterial infections and to guide the antibiotic therapy. In our work, an improved up‐converting nanoparticle (UCP) technology based on the immunochromatographic assay (UPT‐ICA) was developed for rapid and quantitative detection of PCT. In order to further improve the accuracy, sensitivity and stability of the assay on the basis of our previous study, the UCP coupling with monoclonal antibody of PCT (UCP‐Ab1) was freeze‐dried under certain conditions. And the detections of PCT levels with UCP‐Ab1 conjugates before and after freeze‐drying were evaluated. The results show that, compared to the UCP‐Ab1 conjugates without freeze‐drying, the detection sensitivity of freeze‐dried UCP‐Ab1 is slightly improved, having a lower immunochromatogragh background and better stability. This improved method can provide a rapid, accurate, and relatively easy way for the clinical detection of PCT.     

金纳米粒子动态光散射技术的应用研究进展

动态光散射(Dynamic light scattering,DLS)作为颗粒粒径分析方法,具有免分离、易操作、检测成本低、数据易处理等优点;功能化的金纳米粒子除具有本身粒子属性外,还能特异性识别待检物,明显放大检测物光散射信号,可通过DLS技术快速、特异、灵敏检测目标物。该文综述了金纳米粒子DLS技术在目标物分析与检测中应用的研究进展,并对动态光散射技术在应用过程存在的问题进行了讨论,旨在为其实际应用提供一定参考。     

Nano-enabled biosensing systems for intelligent healthcare: towards COVID-19 management

Biosensors are emerging as efficient (sensitive and selective) and affordable analytical diagnostic tools for early-stage disease detection, as required for personalized health wellness management. Low-level detection of a targeted disease biomarker (pM level) has emerged extremely useful to evaluate the progression of disease under therapy. Such collected bioinformatics and its multi-aspects-oriented analytics is in demand to explore the effectiveness of a prescribed treatment, optimize therapy, and correlate biomarker level with disease pathogenesis. Owing to nanotechnology-enabled advancements in sensing unit fabrication, device integration, interfacing, packaging, and sensing performance at point-of-care (POC) has rendered diagnostics according to the requirements of disease management and patient disease profile i.e. in a personalized manner. Efforts are continuously being made to promote the state of art biosensing technology as a next-generation non-invasive disease diagnostics methodology. Keeping this in view, this progressive opinion article describes personalized health care management related analytical tools which can provide access to better health for everyone, with overreaching aim to manage healthy tomorrow timely. Considering accomplishments and predictions, such affordable intelligent diagnostics tools are urgently required to manage COVID-19 pandemic, a life-threatening respiratory infectious disease, where a rapid, selective and sensitive detection of human beta severe acute respiratory system coronavirus (SARS-COoV-2) protein is the key factor.